EGF类生长因子来源的新型靶向肽在抗肿瘤药物蛋白中的应用

发布时间：2018-03-31 07:02

本文选题：肿瘤靶向肽　切入点：牛痘病毒生长因子　出处：《中国生物工程杂志》2017年03期

【摘要】：许多肿瘤细胞表面表皮生长因子受体EGFR都存在过表达现象。考察了牛痘病毒生长因子(VGF)中的EGFR结合域(S3)与人的肝素样表皮生长因子(HB-EGF)来源的肝素结合域(命名为HE)重组后对肿瘤细胞的选择性。通过重组表达带有靶向和穿膜结构域的EGFP-S3-HE和EGFP-S3-HE-TATm两种融合蛋白与正常细胞和肿瘤细胞的共孵育实验来研究其对肿瘤细胞的特异性靶向吸附和穿膜效应。进一步将S3-HE-TATm靶向穿膜序列与苦瓜来源的核糖体失活蛋白MAP30融合,可显著提高MAP30对肿瘤细胞的抑杀作用,但这种抑杀作用却对正常细胞仍保持在较低水平。由此表明S3-HE-TATm是一种新型优异的肿瘤细胞靶向药物运输载体,可用于肿瘤治疗的进一步开发研究。
[Abstract]:The expression of epidermal growth factor receptor (EGFR) on the surface of many tumor cells was investigated. The EGFR binding domain S3 of cowpox virus growth factor (VGF) and heparin binding domain from human heparin-like epidermal growth factor (HB-EGF) were investigated. The specific target for tumor cells was studied by co-incubating EGFP-S3-HE and EGFP-S3-HE-TATm fusion proteins with targeted and transmembrane domains with normal cells and tumor cells. Further fusion of S3-HE-TATm targeted transmembrane sequence with ribosomal inactivated protein MAP30 derived from Momordica charantia L. The inhibitory effect of MAP30 on tumor cells was significantly increased, but the inhibitory effect on normal cells remained at a low level, which indicated that S3-HE-TATm was a novel and excellent drug carrier for tumor cell targeting. It can be used in the further development of tumor therapy.
【作者单位】：华东理工大学生物反应器工程重点实验室;浙江日升昌药业有限公司;上海中医药大学中药研究所;
【分类号】：Q71

【相似文献】